Company News
Iovance Shares Up 3.2% After Australian Approval
Iovance Biotherapeutics' shares jumped 3.2% in after‑hours trading following TGA conditional approval of its melanoma therapy Amtagvi.
The approval marks Amtagvi’s third marketing authorization and th
